|
|
|
|
|
Delatestryl
Houston Chronicle, ...to $87.8 million from $96.4 million last year on lower sales of Oxandrin, a drug to promote weight gain after surgery, and testosterone treatment Delatestryl. ... Indevus to Present at CIBC Annual Biotechnology & Specialty ... Mar 29, 2006 Genetic Engineering News, ...health. The Company currently markets SANCTURA(R) for overactive bladder and DELATESTRYL(R) for the treatment of male hypogonadism. ... Savient Reports Results for the Full Year 2005 Mar 30, 2006 Genetic Engineering News, Completed the sale of Delatestryl(R) to Indevus Pharmaceuticals receiving $5 million plus compensation for existing product inventory as well as potential ... Indevus Announces FDA Acceptance of IND for NEBIDO(R); Company to ... Mar 9, 2006 Genetic Engineering News, ..."We have recently entered the hypogonadism market with our acquisition of DELATESTRYL(R), a short ... Suggested dosing of DELATESTRYL is once every 2 to 4 weeks. ... FDA OKs Indevus' Nebido trial Mar 9, 2006 BusinessWeek ..."We have recently entered the hypogonadism market with our acquisition of Delatestryl, a short-acting injectable testosterone product. ... Delatestryl --> |
|
Home | About | Search topics | Cancers | Treatment | Medications Onconews provides free news and resources on cancer-related topics. Copyright onconews.org 2005-2006. All Rights Reserved. |